Abstract |
A new Soviet antioxidant drug, ubinon, has been used in 75 patients with coronary heart disease (CHD) of functional classes I-III, including 12 patients with ventricular extrasystoles. Treatment with placebo in 10 patients produced no improvement and had no effect on their stress tolerance. Ubinon, taken as 90 and 135 mg/day doses, was shown to produce clinical improvement and raise stress tolerance, mostly in first- and second-class cases. In coronary patients with ventricular extrasystoles, ubinon enhanced antiarrhythmic effect of mexitil. The use of ubinon was accompanied by a drop in blood oxidant activity and a rise in antioxidant activity, an increase in blood 6-keto-PGF1 alpha, a fall in TxB2 and a suppression of platelet activity. In addition, coronary patients with ventricular extrasystoles showed reduced cAMP and cGMP content and elevated cAMP/cGMP ratio.
|
Authors | V A Dudaev, V V Borodkin, A Abbud, I V Diukov |
Journal | Kardiologiia
(Kardiologiia)
Vol. 29
Issue 1
Pg. 48-52
(Jan 1989)
ISSN: 0022-9040 [Print] Russia (Federation) |
Vernacular Title | Primenenie antioksidanta ubinona v kompleksnom lechenii bo'lnykh ishemicheskoĭ bolez'niu serdtsa. |
PMID | 2499730
(Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Antioxidants
- Placebos
- Nitroglycerin
|
Topics |
- Adult
- Aged
- Antioxidants
(administration & dosage)
- Clinical Trials as Topic
- Coronary Disease
(drug therapy, etiology, metabolism)
- Drug Therapy, Combination
- Humans
- Lipid Peroxidation
(drug effects)
- Male
- Middle Aged
- Nitroglycerin
(administration & dosage)
- Placebos
|